Abstract:Abstract Objectives Cyclin-dependent kinase 19 (CDK19) is a component of the mediator coactivator complex, which is required for transcriptional activation. In this study, we utilized public databases and wet-bench hepatic cell line experiments to elucidate the potential roles of CDK19 in hepatocellular cancer (HCC). Materials and methods We studied the relationships between CDK19 expression and several clinical features related to HCC via the Oncomine and UALCAN databases. The prognostic value of CDK19 was tested using the Kaplan–Meier Plotter database. We presented the mutations of CDK19 and addressed the relation of CDK19 expression with immune cell infiltration by means of the cBioPortal, Catalogue of Somatic Mutations in Cancer (COSMIC) and Tumor IMmune Estimation Resource (TIMER) databases. Hub genes were obtained and further analyzed using the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database. To test the in silico findings, we knocked down CDK19 with short hairpin RNA (shRNA) technology in two hepatic cell lines and conducted several functional characterization experiments. Results Marked CDK19 upregulation was found in HCC tissues versus normal liver tissues, and CDK19 mRNA expression had high diagnostic value in HCC patients. Subgroup analysis showed that CDK19 overexpression was associated with sex, tumor stage and TP53 mutation status. The prognostic value of CDK19 upregulation for overall survival (OS) was significant in patients with stage 2–3, stage 3–4, and grade 2 disease. One percent of the patients had CDK19 mutations, but no relationship between CDK19 mutation and prognosis was observed. CDK19 was positively correlated with the abundances of CD4 + T cells, macrophages and dendritic cells. We identified 10 genes correlated with CDK19, 8 of which presented excellent prognostic value in HCC. These hub genes were directly involved in cell division and regulation of the G2/M cell cycle transition. Protein–protein interaction (PPI) and pathway predictions indicated that CDK19 is highly likely to be involved in several cellular functions, such as proliferation, migration, and invasion. These functions were strongly interfered from two independent hepatic cell lines after CDK19 knockdown. Conclusions CDK19 could be a prognostic marker in HCC, and its therapeutic potential in HCC needs further study.

Prp19 Arrests Cell Cycle Via Cdc5L in Hepatocellular Carcinoma Cells.

Pre-mRNA Processing Factor 19 Functions in DNA Damage Repair and Radioresistance by Modulating Cyclin D1 in Hepatocellular Carcinoma

Prp19 Facilitates Invasion of Hepatocellular Carcinoma Via P38 Mitogen-Activated Protein Kinase/twist1 Pathway.

Dna Damage Induces Down-Regulation Of Prp19 Via Impairing Prp19 Stability In Hepatocellular Carcinoma Cells

Prp19 Facilitated P21-Dependent Senescence of Hepatocellular Carcinoma Cells

Increased PRP19 in Hepatocyte Impedes B Cell Function to Promote Hepatocarcinogenesis

Increased Arpp-19 Expression Is Associated With Hepatocellular Carcinoma

Cyclin-dependent Kinase 19 Upregulation Correlates with an Unfavorable Prognosis in Hepatocellular Carcinoma

An Integrated Analysis of the Identified PRPF19 as an Onco-immunological Biomarker Encompassing the Tumor Microenvironment, Disease Progression, and Prognoses in Hepatocellular Carcinoma

The Role of Med19 in the Proliferation and Tumorigenesis of Human Hepatocellular Carcinoma Cells.

ABHD17C Represses Apoptosis and Pyroptosis in Hepatocellular Carcinoma Cells

Human growth hormone and human prolactin function as autocrine/paracrine promoters of progression of hepatocellular carcinoma.

Suppression of Heterogeneous Nuclear Ribonucleoprotein C Inhibit Hepatocellular Carcinoma Proliferation, Migration, and Invasion via Ras/MAPK Signaling Pathway

Inhibition of ribosomal RNA processing 15 Homolog (RRP15), which is overexpressed in hepatocellular carcinoma, suppresses tumour growth via induction of senescence and apoptosis

Mediator Complex Subunit 19 Promotes the Development of Hepatocellular Carcinoma by Regulating the AKT/mTOR Signaling Pathway

Down-regulated long non-coding RNA H19 inhibits carcinogenesis of renal cell carcinoma

Nuclear KRT19 is a Transcriptional Co-Repressor Promoting Histone Deacetylation and Liver Tumorigenesis

Proline-rich Protein 11 Silencing Inhibits Hepatocellular Carcinoma Growth and Epithelial-Mesenchymal Transition Through Β-Catenin Signaling.

RGS19 activates the MYH9/β-catenin/c-Myc positive feedback loop in hepatocellular carcinoma

H19 Promotes HCC Bone Metastasis Through Reducing Osteoprotegerin Expression in a Protein Phosphatase 1 Catalytic Subunit Alpha/p38 Mitogen‐Activated Protein Kinase–Dependent Manner and Sponging microRNA 200b‐3p

Prp19 Is an Independent Prognostic Marker and Promotes Neuroblastoma Metastasis by Regulating the Hippo-YAP Signaling Pathway